Olmesartan 1 A Pharma (Olmesartan Medoxomil)

Olmesartan medoxil selectively blocks the AT1 receptor for angiotensin II, preventing the hormone from causing blood vessels to narrow and reducing aldosterone release. This results in vasodilation, lower peripheral resistance, and a decrease in blood pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood pressure, response to therapy, and any co‑existing medical conditions. Dosage adjustments are made during follow‑up visits.

Olmesartan is contraindicated in pregnancy because it can cause fetal toxicity and injury. Limited data are available for breastfeeding, and the drug is generally not recommended unless the benefit outweighs potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmesartan belongs to the angiotensin II receptor blocker (ARB) class, which unlike ACE inhibitors does not typically cause a dry cough. It offers similar blood‑pressure‑lowering efficacy to other ARBs and is often chosen for patients who are intolerant to ACE inhibitors.

Store the tablets below 25 °C in their original container, protecting them from moisture and direct sunlight. Do not expose the product to excessive heat or humidity to maintain potency.

Olmesartan 1 A Pharma is taken orally, usually once daily, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether to swallow the tablet whole.

Serious adverse events include angio‑edema, severe hypotension, acute kidney injury, and hyper‑kalemia. Prompt medical attention is required if swelling of the face, lips or throat, sudden dizziness, or significant changes in kidney function occur.

Olmesartan should not be used by individuals who are pregnant, have known hypersensitivity to olmesartan or any ARB component, or have severe renal artery stenosis. Clinicians should also exercise caution in patients with advanced kidney disease.